影响因素试验在药物研发中的作用及其关注点

©1994-2010ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.[J].EurJClinPharmacol,2001,57(3):2292234.[14]AMSDENGW,KUYEO,WEIGC.Astudyoftheinteractionpo2tentialofazithromycinandclarithromycinwithatorvastatininhealthyvolunteers[J].JClinPharmacol,2002,42(4):4442449.[15]LEEAJ,MSDDIXDS.Rhabdomyolysissecondarytoadruginter2actionbetweensimvastatinandclarithromycin[J].AnnPharmaco2ther,2001,35(1):26231.[16]CORSINIA,BELLOSTAS,BAETTAR,etal.Newinsightsintothepharmacodynamicandpharmacokineticpropertiesofstatins[J].PharmacolTher,1999,84(3):4132428.[17]ASBERGA,HARTMANNA,FJELDSAE,etal.Bilateralpharma2cokineticinteractionbetweencyclosporineAandatorvastatininre2naltransplantrecipients[J].AmJTransplant,2001,1(4):3822386.[18]FARMERJA,TORRE2AMIONEG.ComparativetolerabilityoftheHMG2CoAreductaseinhibitors[J].DrugSaf,2000,23(3):1972213.[19]NISHIOS,WATANABEH,KOSUGEK,etal.Interactionbetweenamlodipineandsimvastatininpatientswithhypercholesterolemiaandhypertension[J].HypertensRes,2005,28(3):2232227.[20]ZENGS.DrugMetabolism()[M].Zhejiang:Zhe2jiangUniversityPublishingHouse,2004:1752194.[21]LIZD,SHIXJ,WANGDY,etal.Drug2inducedrhabdomyolysis[J].ChinJClinPharm(),2003,12(1):54258.(:2006211222):,,Tel:[phone]E2mail:chenghp@cde1org1cn1,1,2,1(11,100038;21,310058):R944:E:1001-2494(2008)02-0158-03,(ICH)[122];FDA[3][4],,,;,;,,,,,,,,(),,,1,,,3,,,,pH,2211,21111,,,,,,,,;,21112,,,,,;,pH;,;,851ChinPharmJ,2008January,Vol143No1220081432©1994-2010ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(),,(,),,,,95120081432ChinPharmJ,2008January,Vol143No12©1994-2010ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.[1]ICH,Q1A(R2)StabilityTestingforNewDrugSubstanceandProducts[EB/OL]12003,111[2]ICH,Q1BPhotostabilityTestingofNewDrugSubstancesandProducts[EB/OL]11996,111[3]FDA,GuidanceforIndustry:StabilityTestingofDrugSubstanceandDrugProduts,CDER/CBER,draftguidance[EB/OL].1998161[4]Ch1P2005Vol(20051)[S]12005.Appendix,17621791(:2007203215)(94),PEG2pHb,PEG2pHb,,IgEPEG2pHb,,PEG2pHbREFERENCES[1]HUYD,BAIJS,JIAOKF,etal1Studyonpolyethyleneglycolmodifiedporcinehemoglobinusingcomputermodeling[J]1JExpHematol(),2001,9(3):26322671[2]LIJ,ZHANGJJ,WUWT1EffectofDBBFmodifiedporcinehe2moglobinonitsstructureandfunction[J]1ChinPharmJ(),2005,40(16):1267212701[3]LIJ1StudyonthepreparationofbloodsubstitutebymodiyfingporcinehemoglobinwithPEG[D]1Nanjing:ChinaPharmUniv,20061882891[4]ZHANGLX,ZHANGTF,LILY1MethodsandTechnologiesofBiochemicalExperiments()(secondedi2tion)[M]1Beijing:HigherEducationPress,1997:40324061[5]SHENGX,ZHOURL1ModernImmunologicalExperimentalTechnology()[M]1Wuhan:HubeiSci2enceandTechnologyPress,1998:41024121[6]ZHOUXW,HUXJ1InstrumentsAnalysisandExperimentsTech2nologyinBiochemistry()[M]1Beijin:ChemicalIndustryPress,2002:28322841(:2006212221)061ChinPharmJ,2008January,Vol143No1220081432